Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

SILO

Silo Pharma (SILO)

Silo Pharma Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:SILO
일자시간출처헤드라인심볼기업
2024/06/1406:08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SILOSilo Pharma Inc
2024/06/1402:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SILOSilo Pharma Inc
2024/06/1205:00Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SILOSilo Pharma Inc
2024/06/0721:18GlobeNewswire Inc.Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for FibromyalgiaNASDAQ:SILOSilo Pharma Inc
2024/06/0705:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SILOSilo Pharma Inc
2024/06/0705:50GlobeNewswire Inc.Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SILOSilo Pharma Inc
2024/06/0619:07Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SILOSilo Pharma Inc
2024/06/0521:00GlobeNewswire Inc.Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SILOSilo Pharma Inc
2024/06/0505:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SILOSilo Pharma Inc
2024/06/0421:41GlobeNewswire Inc.Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and AnxietyNASDAQ:SILOSilo Pharma Inc
2024/05/2121:45GlobeNewswire Inc.Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse PreventionNASDAQ:SILOSilo Pharma Inc
2024/05/1421:45GlobeNewswire Inc.Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in KetamineNASDAQ:SILOSilo Pharma Inc
2024/05/1405:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SILOSilo Pharma Inc
2024/04/2321:15GlobeNewswire Inc.Silo Pharma Announces Positive Results for Intranasal PTSD TreatmentNASDAQ:SILOSilo Pharma Inc
2024/04/1021:11GlobeNewswire Inc.Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease TherapeuticNASDAQ:SILOSilo Pharma Inc
2024/03/2021:30GlobeNewswire Inc.Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety TherapeuticNASDAQ:SILOSilo Pharma Inc
2024/03/1820:15GlobeNewswire Inc.Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic PainNASDAQ:SILOSilo Pharma Inc
2024/02/2822:25GlobeNewswire Inc.Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSDNASDAQ:SILOSilo Pharma Inc
2024/02/1422:45GlobeNewswire Inc.Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug DeliveryNASDAQ:SILOSilo Pharma Inc
2024/02/0203:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SILOSilo Pharma Inc
2024/02/0200:00GlobeNewswire Inc.Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and NeurologyNASDAQ:SILOSilo Pharma Inc
2024/01/3114:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SILOSilo Pharma Inc
2024/01/2607:29Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:SILOSilo Pharma Inc
2024/01/2607:27Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SILOSilo Pharma Inc
2024/01/2422:55GlobeNewswire Inc.Silo Pharma Announces Positive Results in Alzheimer’s Disease StudyNASDAQ:SILOSilo Pharma Inc
2024/01/2407:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SILOSilo Pharma Inc
2024/01/1202:15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SILOSilo Pharma Inc
2024/01/1006:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SILOSilo Pharma Inc
2024/01/0422:55GlobeNewswire Inc.Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSDNASDAQ:SILOSilo Pharma Inc
2023/12/2822:25GlobeNewswire Inc.Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for FibromyalgiaNASDAQ:SILOSilo Pharma Inc
 검색 관련기사 보기:NASDAQ:SILO